Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company advanced research and development of gene-regulating therapeutics using its proprietary CRISPR-GNDM® technology, and steadily proceeded with the development of key programs and platform technologies.
The filing includes a description of significant events and conditions. Although the company has continuously recorded operating losses and negative operating cash flow and stated that conditions exist that raise significant doubt about its ability to continue as a going concern, it believes that sufficient funds can be secured for the business activities required over the next year and that there is no material uncertainty. There are no matters to be reported in the notes regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Operating profit | ¥-1,000 million |
| Ordinary income | ¥-965 million |
| Profit attributable to owners of the parent | ¥-920 million |
| Net income per share | -¥9.96 |
| Equity ratio | End of the current fiscal period 76.9 / End of previous period 93 |
| Total assets | ¥3,136 million |
| Net assets | ¥2,462 million |
| Cash flows from operating activities | ¥-692,410 thousand |
| Cash flows from investing activities | ¥37,049 thousand |
| Cash flows from financing activities | ¥819,718 thousand |
| Cash and cash equivalents at end of period | ¥3,015,530 thousand |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Impairment loss | ¥1,597 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on collection of written-off receivables ¥36,291 thousand, Gain on sale of non-current assets ¥17,399 thousand / Extraordinary loss Impairment Losses ¥1,597 thousand |
| Disclosure regarding the going concern assumption | The filing includes a description of significant events and conditions. Although the company has continuously recorded operating losses and negative operating cash flow and stated that conditions exist that raise significant doubt about its ability to continue as a going concern, it believes that sufficient funds can be secured for the business activities required over the next year and that there is no material uncertainty. There are no matters to be reported in the notes regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Material subsequent events | Between 1 July 2026 and the end of July, some of the stock acquisition rights with revised exercise price provisions were exercised, and 7,040,000 common shares were issued. Capital stock and capital surplus each increased by ¥115,687 thousand, and the total number of shares issued as of the end of July was 104,374,098. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 97,334,098 |
| Treasury Shares at Period-End | 64 |
| Factors Behind Changes in Business Performance | The company advanced research and development of gene-regulating therapeutics using its proprietary CRISPR-GNDM® technology, and steadily proceeded with the development of key programs and platform technologies. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company stated that it advanced research and development of gene-regulating therapeutics using its proprietary CRISPR-GNDM® technology, and proceeded with the development of key programs including MDL-101. However, it did not specify the factors behind the year-on-year reduction in the operating loss.